Latest news with #TBE
Daily Mirror
15-05-2025
- Health
- Daily Mirror
UK Health Security Agency alert to anyone going out this weekend
People planning on going out, especially for a walk in the park, are being urged to 'check themselves' when coming back home The UK Health Security Agency (UKHSA) is warning people who are planning on going out this weekend, as more warm and sunny weather is forecast, to exercise caution. The mild conditions have meant more people are soaking up the sun and enjoying spending time outdoors; however, for those not careful enough, they could face nasty consequences. According to the Met Office, it will stay "mostly dry and settled with further warm sunshine" on Saturday and Sunday (May 17-18). As the weather heats up, people are being urged to 'check themselves' after coming back home, especially if they've been for a walk in a park. This is because ticks are more active during warmer months, generally from spring through autumn. Taking to X to urge Brits to stay alert, the UKHSA said: "Planning a walk this weekend? #BeTickAware and don't forget the essentials: long sleeves, long trousers, repellent, and tick remover. Ticks are common in grassy, wooded areas, so check yourself regularly during and after your walk." The impact of a tick bite that carries a disease can vary based on several factors. Young children, the elderly, and those with weakened immune systems may experience more severe symptoms. Not every tick poses a threat, however. Although ticks can carry diseases, including the common deer tick found in the UK, many do not carry any. Testing has shown that only about 30 to 35 per cent of deer ticks are infected with Lyme disease (borrelia burgdorferi), and fewer are known to carry babesia or anaplasmosis. Even if a tick is infected, it doesn't necessarily mean it will pass on the disease when it bites. For a tick to transmit these diseases, it needs to be fully embedded and engorged after feeding, which typically takes at least 24 to 36 hours of attachment. What diseases can ticks cause? Ticks pose a significant risk as they can spread several diseases to both humans and animals via their bites. Some well-known tick-borne illnesses are Lyme disease, tick-borne encephalitis (TBE), and Babesiosis. Lyme disease is a bacterial infection primarily spread by deer ticks. Symptoms include fever, fatigue, headaches, and sometimes a distinctive bullseye rash. If not treated, it can result in serious long-term issues like arthritis and heart problems. Another condition is tick-borne encephalitis (TBE). This is a viral infection found mainly in Europe and Asia, presenting with flu-like symptoms and potentially severe complications like brain inflammation. Babesiosis, a parasitic infection caused by ticks, can cause fever and chills. In serious cases, it may harm red blood cells, resulting in hemolytic anaemia. Anaplasmosis is another bacterial infection caused by ticks that can lead to flu-like symptoms and, in severe instances, complications such as pneumonia. Lastly, alpha-gal syndrome is an allergic reaction to red meat triggered by bites from the Lone Star tick. Other dangers of ticks: Tick bites can lead to irritation and discomfort, causing itching, redness, and swelling at the site of the bite. Some people might experience allergic reactions to tick saliva or other tick components, which can result in symptoms like hives, swelling, or even breathing difficulties. Additionally, if a tick bite isn't cleaned or treated properly, it may heighten the risk of secondary infections, such as cellulitis. Some symptoms from bites, like inflammation, may take two to three months to appear. How can you avoid tick bites? Stay clear of areas where ticks are common, particularly in grassy and wooded regions during their peak season in spring and summer. Dress appropriately by wearing long sleeves, long trousers, and closed-toe shoes when venturing into tick-prone environments. Remember to apply insect repellent that contains DEET, picaridin, or IR3535 to any exposed skin. After outdoor activities, make it a habit to check yourself and your pets for ticks, focusing on spots like the armpits, groin, and scalp. If you think you might have a tick-borne illness, it's important to see a doctor. They can help diagnose and treat any symptoms you may have after a tick bite. Your doctor might also suggest some blood tests to check for tick-related diseases. Can you remove a tick? To remove a tick, you should: Use a tick removal device or fine-toothed tweezers to gently grip the tick as close to the skin as possible. Pull steadily away from the skin without crushing the tick. Wash your skin with water and soap afterwards. Apply an antiseptic cream to the skin around the bite. The NHS says: "Many pharmacies and outdoor stores sell tick removal devices. These are useful if you often spend time in areas where there are ticks. If the tick's mouthparts break off in the skin and can't be removed, this may cause irritation, but they should fall out naturally in time. "Do not use a cigarette end, match head, alcohol or petroleum jelly on a tick. Once you've removed a tick, monitor the area where you were bitten. You do not need to speak to your GP if you've been bitten and have no symptoms." You should remove any ticks from yourself or your clothing before washing. You can use tweezers to remove a tick from your clothing or any other fabric (like a carpet or bedding). You could then tightly wrap the tick in tape and put it in an outside bin. You don't need to disinfect clothing that has a tick on it. Where are ticks found? Ticks can be found in various habitats where mammals and birds reside, such as woodlands, moorlands, grassy fields, gardens, and parks. Since they cannot fly or jump, they latch onto animals or humans as they pass by. When is tick season? Tick season typically runs from March to October, but it can extend beyond that due to favourable weather conditions that keep them active longer. It's important to stay vigilant about ticks throughout the year, as some symptoms from bites, like inflammation, may take two to three months to appear.
Yahoo
12-05-2025
- Business
- Yahoo
Bavarian Nordic AS (BVNKF) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...
Revenue: 1.4 billion Danish Krona, representing a 62% growth compared to the previous year. EBITDA Margin: 31%. Public Preparedness Revenue Growth: 83% increase compared to the prior year. Travel Health Revenue Growth: 52% increase over the prior year. Rabies Vaccine Growth: 53% increase. TBE Vaccine Growth: 62% increase. Gross Margin: 51%, a 2% point improvement from the previous year. R&D Costs: Slightly lower than last year, with a full-year guidance of approximately 900 million Danish Krona. SG&A Costs: Increased from 209 million to 250 million Danish Krona. Cash and Cash Equivalents: Approximately 1.2 billion Danish Krona. Full-Year Revenue Guidance: Between 5.7 and 6.7 billion Danish Krona. Full-Year EBITDA Margin Guidance: Between 26% and 30%. Release Date: May 09, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Bavarian Nordic AS (BVNKF) reported a strong start to the year with a 62% growth in revenue, reaching almost 1.4 billion krona. The company achieved an EBITDA margin of 31%, indicating strong profitability. Successful launch and approval of the chikungunya vaccine, Bunya, in the US, Europe, and the UK. Strong performance in the travel health segment, with significant market share gains in rabies and tick-borne encephalitis (TBE) vaccines. Secured a new order from the US government worth $144 million, enhancing revenue stability for 2026. The company is slightly short of the bottom end of the guidance for public preparedness, despite strong performance. Concerns about potential negative impacts from wholesaler stocking in Germany, which could affect future sales. The company faces uncertainties related to potential tariffs and changes in US regulatory policies. There is a cautious approach to travel health growth projections, despite strong Q1 performance, due to seasonality and market dynamics. The company has not yet sold its priority review voucher, indicating potential delays in realizing cash from this asset. Q: Can you explain the factors contributing to the strong EBITDA margin of 31% this quarter, and how does it align with your full-year guidance of 26% to 30%? A: Henrik Juuel, Executive Vice President and CFO, explained that the strong EBITDA margin was due to a smooth quarter in manufacturing, with better yields and higher success rates. The R&D costs are back-end loaded, which also contributed to the margin. The company remains cautious and maintains its full-year guidance of 26% to 30%, acknowledging that the first quarter's performance is close to the upper end of this range. Q: What is the outlook for travel health growth for the year, given the strong performance in Q1? A: Henrik Juuel noted that while Q1 showed strong growth, the company is taking a cautious approach due to the seasonal nature of vaccines. There are no current supply constraints, and the company wants to observe a few more months before revisiting full-year expectations. The 2.5 billion target for the year remains, reflecting a cautious stance despite the strong start. Q: Regarding the chikungunya vaccine, Vinconia, how is the initial feedback, and are there opportunities to capture market share from competitors facing safety concerns? A: Paul Chaplin, President and CEO, acknowledged safety issues with a competitor's product, leading to its suspension for people 65 and older. Bavarian Nordic is in dialogue with French authorities and plans to launch Vinconia in Europe soon. While not changing the guidance for this year, Chaplin noted that increasing chikungunya cases globally could positively impact sales. Q: Have there been any changes in your strategy or interactions with US organizations, particularly concerning tariffs and FDA regulations? A: Paul Chaplin stated that interactions with the US government, particularly Barda, remain business as usual. There have been no changes in FDA policies affecting their pipeline. Regarding tariffs, the company is preparing for potential scenarios but does not expect significant impact due to some manufacturing already being in the US. Q: Can you provide an update on the priority review voucher (PRV) and its potential sale? A: Henrik Juuel confirmed that the PRV has not been sold yet, as the company is not in a rush and wants to ensure it is sold at the right price. There is interest from potential buyers, and the company will proceed with the sale when a suitable offer is made. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
09-05-2025
- Business
- Yahoo
Bavarian Nordic Announces Interim Results for the First Three Months of 2025
COPENHAGEN, Denmark, May 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2025. Revenue for the first three months increased by 62% to DKK 1,347 million, reflecting a strong performance in both Travel Health and Public Preparedness. Travel Health revenue increased by 52% to DKK 680 million compared to the first quarter of 2024, primarily driven by increased demand for rabies and tick-borne encephalitis (TBE) vaccines. Public Preparedness revenue increased by 83% to DKK 629 million compared to the first quarter of 2024. This exceeded initial expectations due to successful efforts to advance the deliveries of a few, but larger, existing orders into the first quarter. Other revenue was DKK 37 million. The operating profit (EBITDA) was DKK 420 million, corresponding to an EBITDA margin of 31%. Financial guidance for the full year is maintained at a revenue of DKK 5,700-6,700 million and an EBITDA margin of 26-30%. DKK million 3m 2025 3m 2024 2025 Guidance Revenue 1,347 831 5,700 – 6,700 EBITDA margin 31% 3% 26-30% Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic said: 'A very strong first quarter for our Travel Health business, demonstrating a 52% growth year-over-year and puts us ahead of our strategic goal of an average annual growth rate of 10-12% for this part of the business until 2027. We also recorded our first US sales of the chikungunya vaccine after its approval in February and ahead of the April recommendation from ACIP. Our phased launch plan for the vaccine is progressing as planned with the first European markets coming online over the next couple of months while we also continue our efforts to expand the regulatory approvals to other territories. Chikungunya represents an increasing public health threat across the globe, and we are proud to have entered our first partnership to improve access to the vaccine for low- and middle-income countries. In Public Preparedness, we also delivered above expectations. While this was largely due to a number of deliveries occurring ahead of plans, it goes to show the strength and scale of our manufacturing setup to meet the increased demand for our mpox/smallpox vaccine.' Highlights from the first quarter Travel Health Vimkunya was approved in the US and EU in February as the first virus-like particle (VLP)-based chikungunya vaccine and the first chikungunya vaccine for persons aged 12 years and older. Additionally, regulatory submissions were filed in the UK and Canada. Vimkunya was launched commercially in the US in March and will be launched in the first European markets later during the first half of 2025. Concurrently with the US approval of Vimkunya, Bavarian Nordic was granted a Priority Review Voucher, which the Company intends to monetize when appropriate. A strategic partnership was entered with Biological E. Limited in February, initially comprising a contract manufacturing agreement with the aim to provide capacity for the future supply of chikungunya vaccines to endemic low- and middle-income countries. Public Preparedness The freeze-dried version of JYNNEOS was approved by the U.S. Food and Drug Administration (FDA) in March for prevention of smallpox and mpox disease in adults 18 years of age and older. The approval supports the ongoing contract with the US government for stockpiling of the vaccine. Other business In January, Bavarian Nordic launched and completed a share buy-back program of DKK 150 million, with the purpose of adjusting the capital structure. Events after the reporting date In April, the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend Vimkunya™ for the prevention of disease caused by chikungunya virus for US persons aged 12 and older traveling to regions with an outbreak or elevated risk of chikungunya, as well as for laboratory workers with potential for exposure to chikungunya virus. In May, the UK Medicines and Healthcare products Regulatory Agency granted marketing authorization in the United Kingdom for Vimkunya® for active immunization for the prevention of disease caused by chikungunya virus in individuals 12 years and older. In May, the US government exercised additional options valued at USD 143.6 million under the existing contract to supply a freeze-dried formulation of JYNNEOS® smallpox vaccine, with planned delivery in 2026. Conference call and webcastThe management of Bavarian Nordic will host an investor/analyst call today at 2 pm CEST (8 am EDT) to present the interim results followed by a Q&A session. A listen-only version of the call and presentation slides can be accessed via To join the Q&A session, please register in advance via Contact investors:Europe: Rolf Sass Sørensen, Vice President Investor Relations, rss@ Tel: +45 61 77 47 43US: Graham Morrell, Paddock Circle Advisors, graham@ Tel: +1 781 686 9600 Contact media:Nicole Seroff, Vice President Corporate Communications, nise@ Tel: +45 53 88 06 03 Company Announcement no. 16 / 2025 About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Attachment Interim Report Q1 2025
Yahoo
09-05-2025
- Business
- Yahoo
Bavarian Nordic Announces Interim Results for the First Three Months of 2025
COPENHAGEN, Denmark, May 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2025. Revenue for the first three months increased by 62% to DKK 1,347 million, reflecting a strong performance in both Travel Health and Public Preparedness. Travel Health revenue increased by 52% to DKK 680 million compared to the first quarter of 2024, primarily driven by increased demand for rabies and tick-borne encephalitis (TBE) vaccines. Public Preparedness revenue increased by 83% to DKK 629 million compared to the first quarter of 2024. This exceeded initial expectations due to successful efforts to advance the deliveries of a few, but larger, existing orders into the first quarter. Other revenue was DKK 37 million. The operating profit (EBITDA) was DKK 420 million, corresponding to an EBITDA margin of 31%. Financial guidance for the full year is maintained at a revenue of DKK 5,700-6,700 million and an EBITDA margin of 26-30%. DKK million 3m 2025 3m 2024 2025 Guidance Revenue 1,347 831 5,700 – 6,700 EBITDA margin 31% 3% 26-30% Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic said: 'A very strong first quarter for our Travel Health business, demonstrating a 52% growth year-over-year and puts us ahead of our strategic goal of an average annual growth rate of 10-12% for this part of the business until 2027. We also recorded our first US sales of the chikungunya vaccine after its approval in February and ahead of the April recommendation from ACIP. Our phased launch plan for the vaccine is progressing as planned with the first European markets coming online over the next couple of months while we also continue our efforts to expand the regulatory approvals to other territories. Chikungunya represents an increasing public health threat across the globe, and we are proud to have entered our first partnership to improve access to the vaccine for low- and middle-income countries. In Public Preparedness, we also delivered above expectations. While this was largely due to a number of deliveries occurring ahead of plans, it goes to show the strength and scale of our manufacturing setup to meet the increased demand for our mpox/smallpox vaccine.' Highlights from the first quarter Travel Health Vimkunya was approved in the US and EU in February as the first virus-like particle (VLP)-based chikungunya vaccine and the first chikungunya vaccine for persons aged 12 years and older. Additionally, regulatory submissions were filed in the UK and Canada. Vimkunya was launched commercially in the US in March and will be launched in the first European markets later during the first half of 2025. Concurrently with the US approval of Vimkunya, Bavarian Nordic was granted a Priority Review Voucher, which the Company intends to monetize when appropriate. A strategic partnership was entered with Biological E. Limited in February, initially comprising a contract manufacturing agreement with the aim to provide capacity for the future supply of chikungunya vaccines to endemic low- and middle-income countries. Public Preparedness The freeze-dried version of JYNNEOS was approved by the U.S. Food and Drug Administration (FDA) in March for prevention of smallpox and mpox disease in adults 18 years of age and older. The approval supports the ongoing contract with the US government for stockpiling of the vaccine. Other business In January, Bavarian Nordic launched and completed a share buy-back program of DKK 150 million, with the purpose of adjusting the capital structure. Events after the reporting date In April, the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend Vimkunya™ for the prevention of disease caused by chikungunya virus for US persons aged 12 and older traveling to regions with an outbreak or elevated risk of chikungunya, as well as for laboratory workers with potential for exposure to chikungunya virus. In May, the UK Medicines and Healthcare products Regulatory Agency granted marketing authorization in the United Kingdom for Vimkunya® for active immunization for the prevention of disease caused by chikungunya virus in individuals 12 years and older. In May, the US government exercised additional options valued at USD 143.6 million under the existing contract to supply a freeze-dried formulation of JYNNEOS® smallpox vaccine, with planned delivery in 2026. Conference call and webcastThe management of Bavarian Nordic will host an investor/analyst call today at 2 pm CEST (8 am EDT) to present the interim results followed by a Q&A session. A listen-only version of the call and presentation slides can be accessed via To join the Q&A session, please register in advance via Contact investors:Europe: Rolf Sass Sørensen, Vice President Investor Relations, rss@ Tel: +45 61 77 47 43US: Graham Morrell, Paddock Circle Advisors, graham@ Tel: +1 781 686 9600 Contact media:Nicole Seroff, Vice President Corporate Communications, nise@ Tel: +45 53 88 06 03 Company Announcement no. 16 / 2025 About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Attachment Interim Report Q1 2025Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-03-2025
- Health
- Yahoo
Experts issue urgent warning about dangerous infections on the rise: 'There is growing concern'
Scientists have confirmed cases of a dangerous brain infection called tick-borne encephalitis in U.K. residents with no travel history, sparking concerns among the public. According to News Medical, a new study by U.K. researchers found that the virus, which spreads by the bite of an infected tick, has become more prevalent in recent years. The team analyzed confirmed cases between 2015 and 2023 and determined that 21 TBE cases were diagnosed in the United Kingdom. From 2022-23, doctors diagnosed 12 patients with the virus, three of whom acquired it locally. Previously, the consensus among scientists was that tick-borne encephalitis was confined to mainland Europe and parts of Asia and that the risk in the U.K. was very low. Until recently, TBE cases in the U.K. had only been observed in residents who have traveled to places where the virus is endemic. "However, the first probable U.K.-acquired cases were reported in 2019 and 2020, and with the virus now present in local tick populations, there is growing concern that the U.K. could see an increase in domestic cases of TBE," the News Medical article explained. While most infections don't cause symptoms, the disease can progress to encephalitis (inflammation of the brain), which can lead to neurological damage, memory loss, and even death in rare cases. Since TBE can cause severe cognitive issues and lifelong health complications, the fact that it's being diagnosed in more patients is concerning, especially since the virus didn't exist in the U.K. until recently. TBEV infections can be more challenging to diagnose than Lyme disease, which may lead to delayed treatment, increasing the risk of long-term health problems. The research team believes our warming planet could be contributing to the spread of tick-borne encephalitis in the U.K. since milder winters allow ticks to survive in larger numbers and expand their geographic range. "Climate change could impact the tick proliferation rate, duration of questing season (and hence transmission) and human behavior among other potential factors," the researchers wrote in the study, published in the journal Eurosurveillance. Rising global temperatures have led to the emergence of other tick-borne illnesses, such as the Heartland virus — a rare disease spread by the lone star tick in America. Two cases of Powassan virus, a disease spread by the black-legged tick, were confirmed last year in Massachusetts and Pennsylvania. While not nearly as common as Lyme disease, experts say cases have increased in recent years because of warmer weather. Do you worry about air pollution in and around your home? Yes — always Yes — often Yes — sometimes No — never Click your choice to see results and speak your mind. If you plan on traveling to a country where TBE is endemic, make sure to get vaccinated before you leave. The U.S. Centers for Disease Control and Prevention also advises wearing long pants and long-sleeved shirts, applying insect repellent, and treating your clothing and gear with permethrin — a synthetic insecticide — if you're engaging in outdoor activities, especially in forested areas. To repel ticks in your backyard without harmful chemicals, you can try planting herbs such as lavender, basil, and oregano. The study authors said that since 2023, TBEV testing has been expanded to all undiagnosed encephalitis cases, even if patients have no exposure to ticks or recent travel history. They suggested further surveillance of ticks and deer across the U.K. to gain more insight on how and where the virus is spreading. If you live in the U.K. or other countries where tick-borne diseases are increasing, keeping tabs on case numbers in your area and other critical climate issues that may impact your health is important. Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.
